Direct Nose-to-Brain Drug Delivery

Mechanism, Technological Advances, Applications, and Regulatory Updates

1st Edition - June 16, 2021
Imprint: Academic Press
Editors: Chandrakantsing Pardeshi, Eliana B. Souto
Language: English
Paperback ISBN:
9 7 8 - 0 - 1 2 - 8 2 2 5 2 2 - 6
eBook ISBN:
9 7 8 - 0 - 1 2 - 8 2 2 5 2 3 - 3

Direct Nose-to-Brain Drug Delivery provides the reader with precise knowledge about the strategies and approaches for enhanced nose-to-brain drug delivery. It highlights the develo… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Direct Nose-to-Brain Drug Delivery provides the reader with precise knowledge about the strategies and approaches for enhanced nose-to-brain drug delivery. It highlights the development of novel nanocarrier-based drug delivery systems for targeted drug delivery to the brain microenvironments with a focus on the technological advances in the development of the novel drug delivery devices for intranasal administration, including special emphasis on brain targeting through nose. This book explores the various quantification parameters to assess the brain targeting efficiency following intranasal administration and includes an overview on the toxicity aspects of the various materials used to develop the direct nose-to-brain drug delivery vehicles and of the regulatory aspects including patents and current clinical status of the potential neurotherapeutics for the effective management of neuro-ailments. Technological advances in new drug delivery systems with diverse applications in pharmaceutical, biomedical, biomaterials, and biotechnological fields are also explained. This book is a crucial source that will assist the veteran scientists, industrial technologists, and clinical research professionals to develop new drug delivery systems and novel drug administration devices for the treatment of neuro-ailments.

Cover image
Title page
Table of Contents
Copyright
Contributors
About the editors
Foreword
Preface
Section I: Basic considerations in nose-to-brain drug delivery
Chapter 1: An overview of anatomical and physiological aspects of the nose and the brain
Abstract
1.1: Introduction
1.2: Nasal anatomy
1.3: Nasal physiology
1.4: Transport pathways from the nose to the central nervous system
1.5: Conclusion
Chapter 2: Direct transport theory: From the nose to the brain
Abstract
2.1: Introduction
2.2: Earlier scenario of direct nose-to-brain drug delivery
2.3: The in vivo biofate of intranasal neurotherapeutics
2.4: Pathways for brain targeting after intranasal administration
2.5: Transport mechanisms
2.6: Clinical investigations to prove direct transport theory
2.7: Concluding remark
Chapter 3: Physicochemical, biopharmaceutical, and practical considerations for efficient nose-to-brain drug delivery
Abstract
3.1: Introduction
3.2: Nasal pathways to the brain
3.3: Barriers to effective naso-brain drug delivery
3.4: Considerations in efficient nose-to-brain drug delivery
3.5: Conclusion and future outlook
Section II: Nanotechnology and naso-brain drug delivery
Chapter 4: Nanomedicines for CNS therapy: Fundamental aspects
Abstract
4.1: Introduction
4.2: The nanotechnology timeline
4.3: Nanotechnology and nanomedicines
4.4: Drawbacks of conventional CNS drug delivery systems
4.5: Rationale for the use of CNS nanomedicines
4.6: Nose-to-brain delivery of nanomedicines
4.7: Designing nanomaterials for nose-to-brain delivery
4.8: Role of nano-sized vectors in nose-to-brain drug delivery
4.9: Nanomedicines: Industrial perspectives
4.10: Future of nanomedicines in nose-to-brain drug delivery
Chapter 5: Nanotechnological advances in direct nose-to-brain drug delivery for neurodegenerative disorders and other neuroailments
Abstract
5.1: Introduction
5.2: Nanotechnology for neuroprotection and neuronal tissue regeneration
5.3: Designing nanomaterials for drug delivery to the CNS
5.4: Nanocarriers for direct nose-to-brain drug delivery
5.5: Nanotechnology-based therapies for neurodegenerative disorders and other neuroailments
5.6: Conclusion and future perspectives
Chapter 6: Surface modification of nanocarriers as a strategy to enhance the direct nose-to-brain drug delivery
Abstract
6.1: Introduction
6.2: Properties of nanocarriers for nose-to-brain drug delivery
6.3: Surface modification of nanomedicines: Drug delivery benefits
6.4: Surface-modified nanomedicines for nose-to-brain drug delivery
6.4: Nano- and neurotoxicity aspects
6.5: Future perspectives and concluding remarks
Chapter 7: Mucoadhesion as a strategy to enhance the direct nose-to-brain drug delivery
Abstract
7.1: Introduction
7.2: Necessity for developing mucoadhesive strategy for direct nose-to-brain drug delivery
7.3: Factors affecting nasal mucociliary clearance
7.4: Mucoadhesion: Theories and mechanism
7.5: Assessment of mucoadhesion
7.6: Mucoadhesive polymer used for intranasal drug delivery
7.7: Modulation of mucoadhesion at nanoscale for direct nose-to-brain drug delivery
7.8: Conclusion and future perspectives
Declaration of interest
Chapter 8: Nanoparticles for direct nose-to-brain drug delivery: Implications of targeting approaches
Abstract
8.1: Introduction
8.2: History of brain targeted drug delivery through the nose
8.3: Targeted drug delivery: General aspects
8.4: Targeting approaches for enhanced nose-to-brain delivery
8.5: Summary and conclusion
Chapter 9: Strategies for enhanced direct nose-to-brain drug delivery
Abstract
9.1: Introduction
9.2: Nasal pathways to the brain
9.3: Strategies for enhanced direct nose-to-brain drug delivery
9.4: Conclusion and future perspectives
Section III: Carriers for direct nose-to-brain drug delivery
Chapter 10: Particulate carriers for nose-to-brain delivery
Abstract
10.1: Introduction
10.2: Microparticles
10.3: Nanoparticles
10.4: Transport mechanisms
10.5: Current scenario and future perspectives
10.6: Conclusion
Chapter 11: Vesicular carriers for direct nose-to-brain drug delivery
Abstract
11.1: Introduction
11.2: Vesicular drug delivery systems
11.3: Vesicular carriers for direct nose-to-brain drug delivery
11.4: Regulatory aspects and clinical translational updates
11.5: Conclusion and future perspectives
Chapter 12: Gel-based delivery of neurotherapeutics via naso-brain pathways
Abstract
12.1: Introduction
12.2: Classification of neurological/brain disorders
12.3: Current prevalence spectrum of neurological disorders
12.4: Mechanism of gelation
12.5: Gel-based systems for brain drug delivery via intranasal administration
12.6: Conclusion and future perspectives
Section IV: Applications of direct nose-to-brain delivery
Chapter 13: Applications of direct nose-to-brain drug delivery in medicine and pharmacy
Abstract
13.1: Introduction
13.2: Potential of intranasal administration in brain targeting
13.3: Formulation strategies for direct nose-to-brain delivery
13.4: Applications of direct nose-to-brain delivery systems
13.5: Market potential of the direct nose-to-brain delivery system
13.6: Conclusion and future perspectives
Chapter 14: Applications of direct nose-to-brain drug delivery in biomedicine, biotechnology, tissue engineering, and immunology
Abstract
14.1: Introduction
14.2: Direct nose-to-brain drug delivery in biomedicine
14.3: Direct nose-to-brain drug delivery in biotechnology, tissue engineering, and immunology
14.4: Concluding remarks
Chapter 15: Diagnostic and theranostic intranasal nanointerventions for brain diseases
Abstract
Acknowledgment
15.1: Introduction
15.2: Intranasal nanodiagnostics and nanotheranostics
15.3: Traumatic brain injury
15.4: Cerebral ischemia
15.5: Conclusion
Chapter 16: Nose-to-brain delivery of biologics and stem cells
Abstract
Acknowledgment
16.1: Introduction
16.2: Nasal cavity
16.3: Barriers and challenges for nose-to-brain delivery of biologics
16.4: Direct nose-to-brain delivery of biologics
16.5: Auxiliary tools to improve the nose-to-brain delivery
16.6: Nasally administered biologics currently on the market
16.7: Conclusion and future perspective
Chapter 17: Applications of nose-to-brain delivery in nanodiagnosis and nanotherapy of neurodegenerative disorders
Abstract
17.1: Introduction
17.2: Nanoparticle-mediated direct nose-to-brain drug delivery
17.3: Neurodegenerative disorders
17.4: Diagnosis of neurodegenerative disorders
17.5: Nanobiosensors for rapid detection of neurodegenerative disorders
17.6: Advanced nanotherapeutics approaches for direct nose-to-brain delivery in neurodegenerative disorders
17.7: Nanotherapy for neuroprotection and neuronal tissue regeneration
17.8: Concluding remarks
Chapter 18: Intranasal gene therapy for the treatment of neurological disorders
Abstract
18.1: Introduction
18.2: Current approaches for the treatment of neurological disorders
18.3: Challenges for gene delivery to CNS
18.4: Intranasal route
18.5: Gene delivery modalities
18.6: Ideal properties of nanomaterials for gene delivery
18.7: Strategies for gene therapy
18.8: Approaches of gene therapy
18.9: Translational medicines
18.10: Concluding remark
Chapter 19: Potential of naso-brain drug delivery in glioblastoma therapy
Abstract
19.1: Introduction: Glioblastoma—A brain tumor and its pathophysiology
19.2: Glioblastoma treatment: Current and nanocarrier-based approaches
19.3: Future trend for the treatment of glioblastoma
Chapter 20: Nose-to-brain delivery of antiretroviral drugs against NeuroAIDS
Abstract
20.1: Introduction
20.2: Neurotropic effects of HIV infection
20.3: HIV-induced neuropathogenesis in NeuroAIDS
20.4: Blood-brain barrier and active efflux transporters in NeuroAIDS
20.5: Intranasal delivery of ARVS to target brain
20.6: Nanotechnology-based approaches for intranasal administration of antiretroviral drugs for NeuroAIDS
20.7: Conclusion
Section V: Technological advances for effective drug administration
Chapter 21: A technology overview on advanced drug administration devices for effective nose-to-brain delivery
Abstract
21.1: Introduction
21.2: Anatomical and physiological obstructions hampering drug delivery to nose
21.3: Advanced drug delivery devices for brain drug delivery via intranasal administration: Technology overview
21.4: Assessment of nasal drug delivery devices
21.5: Patents on nasal drug delivery devices
21.6: Conclusion and future outlook
Section VI: Evaluation of direct nose-to-brain drug delivery
Chapter 22: Experimental models for evaluation of direct nose-to-brain drug delivery
Abstract
22.1: Introduction
22.2: Models for evaluation of direct nose-to-brain drug delivery
22.3: Summary and conclusion
Chapter 23: Quantitative and qualitative analysis of direct nose-to-brain drug delivery
Abstract
23.1: Introduction
23.2: Calculation of drug dose for nose-to-brain delivery
23.3: Analysis of drug following nose-to-brain delivery
23.4: Compartmental pharmacokinetic modeling
23.5: Concluding remarks
Section VII: Toxicity and regulatory aspects
Chapter 24: Toxicity aspects: Crucial obstacles to clinical translation of nanomedicines
Abstract
24.1: Introduction
24.2: Challenges of nanocarriers in clinical translation
24.3: Mechanistic aspects of toxicity
24.4: Biocompatibility/safety assessment
24.5: Strategies to overcome toxicity and paving the way for commercialization
24.6: Conclusion
Chapter 25: Nose-to-brain drug delivery: Regulatory aspects, clinical trials, patents, and future perspectives
Abstract
25.1: Introduction
25.2: Policies/role of regulatory agencies in intranasal drug delivery
25.3: Marketed nasal products for brain disorder or disease
25.4: Patents on nasal products for brain disorder/diseases
25.5: Current status of clinical trials
25.6: Conclusion and future prospective
Index

Chandrakantsing Pardeshi

Dr. Chandrakantsing Pardeshi holds PhD degree in Pharmaceutical Sciences from Kavayitri Bahinabai Chaudhari North Maharashtra University (KBC NMU, India). Presently, he is an Associate Professor of Pharmaceutics at R. C. Patel Institute of Pharmaceutical Education and Research (Shirpur, India) where he is inventing the novel devices for direct nose-to-brain drug delivery. Dr. Pardeshi has authored more than 50 peer-reviewed publications, 21 book chapters and several research abstracts. He has, to his credit, 2 Indian patents and 1 research project funded by University Grants Commission (New Delhi, India). He is an active referee and editorial board member of few reputed multidisciplinary international journals. Dr. Pardeshi also contributed as a Grant evaluator in Government Funding bodies. He has been awarded with Gold Medal from KBC NMU (India), and Excellence Award from Indian Drug Manufacturer’s Association (IDMA, India).

Affiliations and expertise

Kavayitri Bahinabai Chaudhari North Maharashtra University, Jalgaon, India

Eliana B. Souto

Eliana B. Souto is Habil. Professor from the Department of Pharmaceutical Technology of the Faculty of Pharmacy of University of Porto. Prof. Souto graduated in Pharmaceutical Sciences from University of Coimbra (2000), is holder of a master’s in science degree in Pharmaceutical Technology from University of Porto (2002), and PhD in Pharmaceutical Nanotechnology and Biopharmaceutics from the Institut fuer Pharmazie der Freie Universitaet Berlin, Germany (2005). Her research lines include the design, development, and characterization of new drug delivery systems to overcome biological barriers. Prof. Souto serves as Associate Editor, member of the Editorial Board, and Reviewer of several international scientific journals and has published more than 500 works (original and review papers, books and book chapters) in the field of nanosciences and nanomedicine. Prof. Souto also acts as independent expert for several national, European and international funding agencies, and as consultant for pharmaceutical industry.

Affiliations and expertise

Professor, Department of Pharmaceutical Technology of the Faculty of Pharmacy, University of Porto, Portugal

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health